Results 21 to 30 of about 3,869 (167)

Use of levosimendan in hemodynamic management of heart failure in two neonates with intracranial arteriovenous shunts: a case series

Italian Journal of Pediatrics, 2023
Background The hemodynamic status of newborns with intracranial arteriovenous shunts (AVSs) may be extremely complex. Mini-invasive hemodynamic monitoring through innovative techniques such as Near-Infrared Spectroscopy (NIRS) and Pressure Recording ...
Francesca Landolfo, Paola Giliberti, Domenico Umberto De Rose, Flaminia Pugnaloni, Alessandra Santisi, Claudia Columbo, Ludovica Martini, Maria Paola Ronchetti, Luca Di Chiara, Alessandra Toscano, Carlo Gandolfo, Andrea Dotta, Irma Capolupo   +12 more
doaj   +1 more source

The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery

Journal of Cardiovascular Development and Disease, 2023
Background: Postoperative myocardial dysfunction following cardiac surgery is a relatively common occurrence. Levosimendan, a calcium sensitizer and inotropic drug, has shown potential in improving outcomes for patients with low preoperative ejection ...
Vasileios Leivaditis, Konstantinos Grapatsas, Anastasia Papaporfyriou, Michail Galanis, Efstratios Koletsis, Nikolaos Charokopos, Erich Haussmann, Vladislav Kaplunov, Athanasios Papatriantafyllou, Manfred Dahm   +9 more
doaj   +1 more source

Comparison of Levosimendan, Milrinone and Dobutamine in treating Low Cardiac Output Syndrome Following Valve Replacement Surgeries with Cardiopulmonary Bypass [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Low Cardiac Output Syndrome (LCOS) following Cardiopulmonary Bypass (CPB) is common and associated with increased mortality. Maintenance of adequate cardiac output is one of the primary objectives in management of such patients. Aim: To
Sunny, Mohd Yunus, Habib Md Reazaul Karim, Manuj Kumar Saikia, Prithwis Bhattacharyya, Samarjit Dey   +5 more
doaj   +1 more source

Potentiating Cerebral Perfusion Normalizes Glymphatic Dynamics in Systemic Inflammation. [PDF]

Adv Sci (Weinh)
LPS‐induced systemic inflammation increases glymphatic influx but delays cervical lymphatic drainage, accompanied by AQP4 depolarization and impaired glymphatic clearance. Enhancing cerebral blood flow via the inotropic agent levosimendan effectively restored AQP4 polarization, improving glymphatic flux and amyloid‐β clearance.
Zhao R, Sun B, Wei P, Sun Y, He Q, Zhang K, Lu J, Zhu S, Yang Y, Guo Z.   +9 more
europepmc   +2 more sources

Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement

Annals of Cardiac Anaesthesia, 2018
Context: Inhaled levosimendan may act as selective pulmonary vasodilator and avoid systemic side effects of intravenous levosimendan, which include decrease in systemic vascular resistance (SVR) and systemic hypotension, but with same beneficial effect ...
Tanveer Singh Kundra, P S Nagaraja, K S Bharathi, Parminder Kaur, N Manjunatha   +4 more
doaj   +1 more source

Levosimendan in Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia, 2005
Levosimendan is a new calcium sensitizer with inodilatory properties. There is growing clinical experience with levosimendan given to cardiac surgical patients. The aim of this report was to evaluate the effects of perioperative use of levosimendan in surgical patients with high perioperative risk, compromised left ventricular (LV) function, or ...
Harjola, V, Siirilä, K, Suojaranta-Ylinen, R   +2 more
openaire   +2 more sources

Levosimendan for sepsis-induced myocardial dysfunction: friend or foe?

Frontiers in Cardiovascular Medicine
Sepsis-induced myocardial dysfunction (SIMD) involves reversible myocardial dysfunction. The use of inotropes can restore adequate cardiac output and tissue perfusion, but conventional inotropes, such as dobutamine and adrenaline, have limited efficacy ...
Xinxin Du, Xinxin Du, Fang Xiong, Yafei Hou, Xiangyou Yu, Pengfei Pan   +5 more
doaj   +1 more source

Le lévosimendan en cardiologie et chirurgie cardiaque sous circulation extracorporelle

Avicenna Medical Research, 2023
Introduction : le lévosimendan est un agent inodilatateur utilisé avec succès dans le traitement de l’insuffisance cardiaque aigue et chronique.
Sayad, M Abdelbaki, Mehyaoui
doaj   +1 more source

Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure

Pulmonary Circulation, 2017
Levosimendan is an inotropic and vasodilator drug, which is known to improve cardiac function in animal models of right ventricular (RV) failure. The effects of levosimendan on oxygen consumption and myocardial efficiency in the failing RV is unknown. We
Mona S. Hansen, Asger Andersen, Lars P. Tolbod, Nils H. Hansson, Roni Nielsen, Anton Vonk-Noordegraaf, Jens Erik Nielsen-Kudsk   +6 more
doaj   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source